Heterocyclic Compounds

Matches 1 - 50 out of 35,713	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2023/175632A1	SOLID STATE FORMS OF (5S,6S,9R)-5-AMINO-6-(2,3DIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-CYCLOHEPTA[B]PYRI DIN-9-YL 4-(2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-1-YL)-1-PIPERIDINECARBOXYLATE HEMISULFATE AND PROCESSES FOR PREPARATION THEREOF The present invention relates to new solid state forms of (5S,6S,9R)-5-amino-6- (2,3difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyr idin-9-yl 4-(2-oxo-2,3-dihydro- 1H-imidazo[4,5-b] pyridin-1-yl)-1-piperidinecarboxylate hemisulf...
WO/2023/176609A1	COMPOSITION, FILM, OPTICAL FILTER, SOLID-STATE IMAGING ELEMENT, IMAGE DISPLAY DEVICE, INFRARED SENSOR, CAMERA MODULE, AND COMPOUND This composition includes an infrared absorbing agent, a curable compound, and a solvent, wherein the infrared absorbing agent includes a compound represented by formula (1). Provided are a film, an optical filter, a solid-state imaging ...
WO/2023/174329A1	HETEROAROMATIC COMPOUNDS AS PKMYT1 INHIBITORS AND USE THEREOF Providing compounds of Formula (A) or pharmaceutically acceptable salts, solvate, stereoisomer, or isotopic variant thereof useful as PKMYT1 inhibitors, pharmaceutical compositions comprising the same, and use thereof in the manufacture ...
WO/2023/177451A1	COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES Disclosed herein are compounds of Formula (I): Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for cyclin-dependent kinas...
WO/2023/178256A1	TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN) IN PEDIATRIC PATIENTS WITH MIRDAMETINIB The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib o...
WO/2023/178099A1	NLRP3 MODULATORS Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
WO/2023/178269A1	TREATMENT OF CUTANEOUS NEUROFIBROMAS WITH MIRDAMETINIB The present disclosure relates to methods for treating cutaneous neurofibromas (cNF) comprising administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
WO/2023/174314A1	USE AND TREATMENT METHOD OF AZETIDINE DERIVATIVE Provided is the use of a compound of formula I, a pharmaceutically acceptable salt, a stereoisomer, a polymorph, a solvate, a metabolite or a prodrug thereof, or a composition thereof in the preparation of a drug for treating alopecia su...
WO/2023/178285A1	TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
WO/2023/174250A1	4- (AMINOMETHYL) -6- (1-METHYL-1H-PYRAZOL-4-YL) ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 This disclosure provides compounds containing 4- (aminomethyl) -6- (1-methyl-1H-pyrazol-4-yl) isoquinolin-1 (2H) -onestructure, the use thereof for selectively inhibiting the activity of PRMT5 in cooperative with MTA in tumors bearing MT...
WO/2023/174300A1	CRYSTAL FORM OF BTK INHIBITOR, ACID SALT THEREOF, AND CRYSTAL FORM OF ACID SALT THEREOF Disclosed in the present invention are a crystal form of a BTK inhibitor, an acid salt thereof, and a crystal form of the acid salt thereof. The crystal form of a compound of formula I in the present invention is a free alkali crystal fo...
WO/2023/174406A1	NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to a nitrogen-containing heterocyclic derivative EGFR inhibitor, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by general formula (I)...
WO/2023/174374A1	FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF The present disclosure relates to a fused heterocyclic compound, and a preparation method therefor and a medical use thereof. Specifically, the present disclosure relates to a fused heterocyclic compound shown in general formula (I), a p...
WO/2023/173136A2	SMALL MOLECULE INHIBITORS OF THE CRL4 UBIQUITIN LIGASE Compounds of formula (I), compounds of formula (II), and compounds of formula (III) are disclosed. Also disclosed are compounds, compositions, and methods to inhibit CUL4A expression or activity, CUL4B expression or activity, and/or DDB1...
WO/2023/173124A1	NOVEL PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR, COMPOSITIONS COMPRISING THE SAME, METHODS OF MAKING, AND METHODS OF TREATING A DISEASE Aspects disclosed herein relate to compositions comprising novel phosphoinositide 3-kinase (PI3K) inhibitors, and methods of making the novel PI3K inhibitors. Further, various aspects relate to one or more methods of treating a disease u...
WO/2023/169371A1	COMPOUND HAVING BENZYLOXY ARYL ETHER STRUCTURE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed in the present invention are a compound having a benzyloxy aryl ether structure, and a preparation method therefor and the use thereof. The structure of the compound having the benzyloxy aryl ether structure is as represented b...
WO/2023/169535A1	HEPATITIS B ANTIVIRAL AGENTS The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit the protein (s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life ...
WO/2023/168686A1	SUBSTITUTED CYCLOPENTANES AS CDK2 INHIBITORS The present disclosure provides a compound represented by structural formula (I) : or a pharmaceutically acceptable salt, or a stereoisomer thereof and their use in, e.g. treating a disease or disorder associated with CDK2. This disclosu...
WO/2023/173083A1	TETRAHYDROINDOLE DERIVATIVES AS EGFR AND/OR HER2 INHIBTORS USEFUL FOR THE TREATMENT OF CANCER This disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt that inhibits epidermal growth factor receptor (EGER, ERBB1) and/or Human epidermal growth factor receptor 2 (HER2, ERBB2). These compounds of formu...
WO/2023/169456A1	HETEROCYCLIC GLP-1 AGONISTS This disclosure relates to GLP-1 agonists, pharmaceutical compositions, and methods of use thereof.
WO/2023/169226A1	SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF Provided are substituted tricyclic compounds as PARP inhibitors and the use thereof. The compounds represented by Formula (I) as below, wherein, the ring Z, Z1, Z2, Z3, Z4, Z5, A1, A2, A3, L and Cy are defined herein. The compounds of Fo...
WO/2023/172846A1	PPARG INVERSE AGONISTS AND USES THEREOF Provided are compounds of Formula (I):and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with PPARG.
WO/2023/172667A2	SUBSTITUTED IMIDAZO[1,5-a]PYRIDINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME The present disclosure provides substituted imidazo[1,5-a]pyridine N-heterocyclic carbene (NHC) ligands, catalyst complexes thereof, and methods using same. The present disclosure further provides synthetic methods of preparing N-heteroc...
WO/2023/169964A1	USE OF PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS NITRIFICATION INHIBITOR Use of pyrazolo[3,4-b]pyridine compounds as nitrification inhibitor The use of pyrazolo[3,4-b]pyridine compounds as nitrification inhibitor.
WO/2023/169554A1	METHIONINE ADENOSINE TRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF Provided in the present application are a methionine adenosine transferase inhibitor, a pharmaceutical composition containing same, and the use thereof. The compound of the present application has excellent MAT2a enzyme inhibitory activi...
WO/2023/172921A1	SOLID FORMS, SALTS, AND PROCESSES OF PREPARATION OF A CDK2 INHIBITOR The present application provides solid forms and salts of a compound of Formula (I): (I) pharmaceutical compositions thereof, methods of treating a disease or disorder associated with CDK2 using the same, and processes of preparing the c...
WO/2023/169488A1	PHARMACEUTICAL COMBINATION COMPRISING PYRIDO [1,2-A] PYRIMIDINONE COMPOUND AND EGFR INHIBITOR The present application relates to the field of pharmaceutical chemistry, and provides a pharmaceutical combination comprising a pyrido [1,2-a] pyrimidinone compound and an EGFR inhibitor. Specifically, the pharmaceutical combination com...
WO/2023/169569A1	TRICYCLIC HETEROCYCLE COMPOUNDS AS IAP ANTAGONISTS The present disclosure relates to compounds that inhibit IAP (preferably cIAP1, cIAP2 or XIAP) protein, pharmaceutical compositions comprising the same and methods of using the IAP protein inhibitors in the treatment of diseases and cond...
WO/2023/172663A1	SOLID STATE FORMS OF TOLEBRUTINIB AND OF TOLEBRUTINIB SALTS The present disclosure encompasses solid state forms of Tolebrutinib and of Tolebrutinib salts, in embodiments crystalline polymorphs of Tolebrutinib and of Tolebrutinib salts, processes for preparation thereof, and pharmaceutical compos...
WO/2023/170724A1	USE OF SUBSTITUTED QUINOLONE DERIVATIVES FOR TREATING CANCER There is provided a novel use of a substituted quinolone compound of the general formula (I), or a pharmaceutically acceptable salt thereof for treatment of cancer. The prepared substituted quinolones with dual anti-inflammation/free rad...
WO/2023/173016A1	KRAS INHIBITORS FOR TREATING DISEASE The present disclosure relates to diaryl compounds targeting KRAS, pharmaceutical compositions containing the compounds, and methods of using such compounds to treat disease, such as cancer.
WO/2023/169436A1	BENZO BICYCLIC COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF Disclosed in the present invention are a benzo bicyclic compound, and a preparation method and application thereof. Specifically disclosed is a compound, which is a compound as shown in formula (X), or a stereoisomer, geometric isomer, t...
WO/2023/129933A3	6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS The present disclosure relates to 6,6-fused heterocyclic compounds and related compounds and their use in treating a disease or condition responsive to modulation or inhibition of METTL3.
WO/2023/169438A1	NITROGEN-CONTAINING HETEROCYCLIC CELL CYCLE INHIBITOR COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF The invention relates to nitrogen-containing heterocyclic compounds as well as a preparation method therefor and the use thereof, in particular to a nitrogen-containing heterocyclic compound represented in general formula (I), or a pharm...
WO/2023/108165A3	METHODS OF TREATING ADDICTION AND NEUROLOGICAL DISORDERS Embodiments include therapeutic small molecules for use in treating addiction and neurological disorder by stimulating neuroplasticity. The therapeutic small molecule can increase neuroplasticity and improve neural function by affecting ...
WO/2023/169547A1	DNA POLYMERASE θ INHIBITOR AND USE THEREOF A nitrogen-containing heterocyclic compound represented by formula (I-c), or a stereoisomer, a deuterated compound or a pharmaceutically acceptable salt, and a pharmaceutical composition thereof. Also provided is a use of the compound in...
WO/2023/165504A1	DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF Described herein are DGKalpha inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with DGKalpha.
WO/2023/165509A1	DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF Described herein are DGKalpha inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with DGKalpha.
WO/2023/168378A1	PI3KA INHIBITORS The present disclosure provides compounds, compositions, and methods useful for inhibiting PI3Ka, and/or treating a disease, disorder, or condition associated with PI3Ka, and/or treating cancer. (Formula I)
WO/2023/167279A1	METHOD FOR CONTROLLING HARMFUL ARTHROPODS OR HARMFUL NEMATODES USING ZOANTHAMINE ANALOG The present invention provides a method for controlling harmful arthropods or harmful nematodes. Compounds represented by formula (I) [in the formula, R1 represents a hydrogen atom, etc., R2 represents ORA2, R3, R7, R14, R17, R19, and R2...
WO/2023/166450A1	NOVEL HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME The present invention relates to a compound represented by chemical formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof, and a pharmaceutical composition comprising same.
WO/2023/165079A1	DIPYRIDINOPHENAZINE THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIAL DOPED WHITE ELECTROLUMINESCENT DEVICE The present invention relates to a dipyridinophenazine thermally activated delayed fluorescent material doped white electroluminescent device, which is obtained by sequentially carrying out vacuum evaporation on a hole injection layer, a...
WO/2023/167475A1	IMPROVED PREPARATION METHOD FOR RUCAPARIB The present invention relates to an improved preparation method for rucaparib, enabling excellent synthesis yield and reproducibility to be achieved. More particularly, the present invention relates to: an improved preparation method for...
WO/2023/165525A1	DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF Provided are DGKalpha inhibitors and pharmaceutical compositions comprising said inhibitors. The compounds and compositions are useful for the treatment of a disease or disorder associated with DGKalpha.
WO/2023/165493A1	NAPHTHYRIDINE DERIVATIVE AND USE THEREOF Disclosed are a naphthyridine derivative and use thereof. The naphthyridine derivative can well inhibit ATR kinase activity and can be used in the preparation of an ATR kinase inhibitor, particularly in the preparation of a medicament ag...
WO/2023/165077A1	THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIAL BASED ON DIPYRIDINOPHENAZINE ACCEPTOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to a thermally activated delayed fluorescent material based on a dipyridino[3,2-a:2',3'-c]phenazine acceptor and a preparation method therefor. The thermally activated delayed fluorescent material is 11-(9,9...
WO/2023/167234A1	COMPOUND, ORGANIC THIN FILM, PHOTOELECTRIC CONVERSION ELEMENT, IMAGING ELEMENT, PHOTOSENSOR AND SOLID-STATE IMAGING DEVICE The present invention provides a compound which is represented by formula (1) (wherein each of R1 to R6 independently represents a hydrogen atom, a halogen atom, a linear, branched or cyclic alkyl group, or the like).
WO/2023/165570A1	CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF The present invention relates to a compound of formula (I) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutical composition thereof, and a use of the compound...
WO/2023/165501A1	CRYSTAL FORM OF AZD5305, PREPARATION METHOD THEREFOR, AND USE THEREFOR The present application relates to the field of chemical synthesis of pharmaceutics. Specifically, the present application relates to a crystal form of AZD5305, a preparation method therefor, and use thereof. The crystal form provided by...
WO/2023/165438A1	TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF The present invention relates to a substituted tricyclic derivative, a preparation method therefor, and pharmaceutical use of a pharmaceutical composition comprising same. Specifically, the present invention relates to a substituted tric...

Matches 1 - 50 out of 35,713	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >